Fundraising Fox

Lungpacer

Exton, US · 1 known investors

lungpacer.com ↗

Lungpacer develops AeroPace, a temporary transvenous diaphragm neurostimulation system that stimulates the phrenic nerves controlling the diaphragm through a catheter-based approach. The device is used in critical care settings to support independent breathing and assist with weaning patients off mechanical ventilators.

HardwareHealthtechMedical Devicesin /lungpacer-medical-inc.@lungpacer

Founders & leadership

DG
Douglas G. EvansChief Executive Officer and President
VT
Viral ThakkarChief Operations Officer
RD
Rosemarie DhavaleChief Financial Officer and Vice President of HR
SK
Shannon KaustinenDirector of Finance
JC
Jonathan ConlinSecretary

Board

JP
Jan PensaertBoard director
BD
Bob DonohueBoard director
GD
Guillaume DarnandBoard director
CK
Christopher KipleChair of the Board
JW
Joseph W. KaufmannBoard director
ML
Michael L. FavetBoard director

Investors · 1

Keiretsu ForumSan Francisco · $250K – $2M

Competitors · 4

by search overlap
Rf Surgical12 shared keywordsMedtronic develops healthcare technology, including pulsed field ablation systems used to treat atrial fibrillation (AFib). The company serves clinicians and healthcare providers in the medical device and cardiac care field.
Synapse Biomedical Inc.12 shared keywordsSynapse Biomedical develops and commercializes neurostimulation medical devices, including the NeuRx Diaphragm Pacing System (DPS), which uses electrical stimulation of the diaphragm to treat chronic respiratory insufficiency in patients with spinal cord injuries and ALS. The company serves clinicians and patients dependent on mechanical ventilation.
Oup11 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Massdevice10 shared keywordsMassDevice is a news and media outlet covering the medical device industry, publishing articles, special reports, and white papers on medtech companies, products, and regulatory topics such as FDA 510(k) submissions. It serves medical device professionals with industry news and analysis.

Companies competing with Lungpacer for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$137.4M disclosed across 6 rounds · 2017–2026

▶$16MraisedJul 2026 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas G. EvansExecutive Officer, Director
  • Joseph W. KaufmannDirector
  • Bob DonohueDirector
  • Christopher KipleExecutive Officer
  • Jan PensaertDirector
  • Jonathan ConlinExecutive Officer
  • Steven E. PfanstielExecutive Officer
  • Viral ThakkarExecutive Officer
Offering amount
$20M
Amount sold
$16M
First sale
Apr 2026
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedApr 2025 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan PensaertDirector
  • Jonathan ConlinExecutive Officer
  • Bob DonohueDirector
  • Douglas G. EvansExecutive Officer, Director
  • Viral ThakkarExecutive Officer
  • Rosemarie DhavaleExecutive Officer
  • Christopher KipleExecutive Officer, Director
  • Joseph W. KaufmannDirector
Offering amount
$10M
Amount sold
$10M
First sale
Mar 2025
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16MraisedDec 2022 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph KaufmannDirector
  • Josh MakowerDirector
  • Jose Calle GordoDirector
  • Karen LongDirector
  • Christopher KipleExecutive Officer, Director
  • Douglas G. EvansExecutive Officer, Director
  • Jonathan ConlinExecutive Officer
  • Bob DonohueDirector
  • Nawzer MehtaExecutive Officer
  • Rosemarie DhavaleExecutive Officer
Offering amount
$21.1M
Amount sold
$16M
First sale
Dec 2020
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedApr 2022 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Josh MakowerDirector
  • Chris KipleExecutive Officer, Director
  • Valeska SchroederDirector
  • Rosemarie DhavaleExecutive Officer
  • Lesley FronioExecutive Officer
  • Douglas G. EvansExecutive Officer, Director
  • Jonathan ConlinExecutive Officer
  • Joseph W. KaufmannDirector
  • Bob DonohueDirector
  • Jose Calle GordoDirector
  • Nawzer MehtaExecutive Officer
Offering amount
$30M
Amount sold
$20M
First sale
Apr 2022
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55.8MraisedMay 2019 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan ConlinExecutive Officer
  • Josh MakowerDirector
  • Guillaume DarnandDirector
  • Michael FavetDirector
  • Joseph W. KaufmannDirector
  • Douglas EvansExecutive Officer, Director
Offering amount
$65M
Amount sold
$55.8M
First sale
Apr 2019
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.6MraisedJun 2017 · 15 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas EvansExecutive Officer, Director
  • Shannon KaustinenExecutive Officer, Director
  • Michael L. FavetDirector
  • Guillaume DarnandDirector
Offering amount
$19.6M
Amount sold
$19.6M
Proceeds to insiders
$173.5K
First sale
May 2017
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Lungpacer do?
Lungpacer develops AeroPace, a temporary transvenous diaphragm neurostimulation system that stimulates the phrenic nerves controlling the diaphragm through a catheter-based approach. The device is used in critical care settings to support independent breathing and assist with weaning patients off mechanical ventilators.
Who are Lungpacer's investors?
Lungpacer's investors include Keiretsu Forum.
How much funding has Lungpacer raised?
Lungpacer has disclosed $137.4M raised across 6 rounds.
Where is Lungpacer headquartered?
Lungpacer is headquartered in Exton, US.